Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the deal terms, the Biomedicine Discovery Institute of Monash University will lead the antibody discovery campaign for targeting two GPCRs, which are said to be traditionally hard to target.

Ono Pharmaceutical will have exclusive global rights for the development and commercialisation of some existing antibodies developed by Monash University, besides any antibodies developed as a result of the collaboration.

Ono Pharmaceutical Discovery & Research senior executive officer / executive director Toichi Takino said: “We appreciate Monash University’s sophisticated technologies for antibody discovery which enables the creation of therapeutic antibodies using monoclonal antibodies against GPCR.

“Through this collaboration with Monash University, we expect to increase the efficiency of finding new drug candidates that fulfil unmet medical needs in autoimmune and inflammatory diseases.”

Monash University will receive an upfront payment from Ono Pharmaceutical in addition to research funding that will be provided during the option period.

Monash University will also receive milestone payments on clinical development and sales progress, along with royalties based on net sales of the products in the future, if the option is exercised by Ono Pharmaceutical under the deal.

Monash University Biomedicine Discovery Institute senior research fellow Dr Remy Robert said: “We are excited to partner with Ono Pharmaceutical and combine our expertise in anti-GPCR antibody discovery with Ono’s exceptional capabilities in drug development.

“We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.